 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...

PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56...

Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

Liberty Health Sciences (OTCMKTS:LHSIF - Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will...

Petros Pharmaceuticals (NASDAQ:PTPI) & Liberty Health Sciences (OTCMKTS:LHSIF) Critical Review

Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC...

Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Petros Pharmaceuticals enters AI-licensing agreement with software provider

AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider

FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc...

Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Petros Pharmaceuticals (PTPI Research Report), Ath...

Analysts' Top Healthcare Picks: Petros Pharmaceuticals (PTPI), Athira Pharma (ATHA)

Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA(R) working to become the first erectile...

Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Volume (M)	152,623.00
52-Wk High	$7.14
52-Wk Low	$0.6401

PTPI Petros Pharmaceuticals Inc

About

Feed

News

Fundamentals